Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib, Trametinib, and Panitumumab in BRAF-mutant Colorectal Cancer
NCT01750918Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib and trametinib in colorectal cancer (CRC) (6 arms), sponsored by Novartis. Primary endpoints: Number of Participants With Adverse Events at 90 months, Overall Response Rate at 90 months and 1 more. Started Dec 2012; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01750918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01750918.